Cancer-related anemia (CRA) is one of the common accompanying diseases of malignant tumors. In 2019, a cross-sectional survey on the anemia status of 7324 malignant tumor patients in 97 hospitals in China found that the incidence of CRA was about 49.24%. 92.84% of the patients have not been given enough attention and effective treatment. According to the European Oncological Anemia Survey, CRA has the highest incidence in leukemia patients, followed by lymphoma/myeloma. CRA not only leads to a decline in the quality of life of patients, but also reduces the sensitivity to radiotherapy and chemotherapy, and also causes hypoxia in tumor tissue, which affects the prognosis of patients as an independent factor. At present, the treatment of CRA mainly includes blood transfusion therapy, erythropoiesis-stimulating agent (ESA) therapy, iron supplementation, etc. Conventional oral iron has low bioavailability and strong gastrointestinal irritation. Although intravenous iron can quickly replenish iron, excessive iron supplementation is prone to iron overload. Less acceptable. Shengxuening Tablets are derived from silkworm excrement. The main components of iron chlorophyllin and chlorophyll derivatives are very similar in structure to heme, and can be directly absorbed by small intestinal mucosal cells, effectively supplementing the iron elements required in the process of hematopoiesis. The investigators found that Shengxuening Tablets can increase the number of peripheral blood cells in mouse models of myelosuppression, improve bone marrow morphology, reverse the decrease in body weight and spleen index, and increase the levels of serum erythropoietin and granulocyte-macrophage colony-stimulating factor . Real-time fluorescent quantitative PCR and Western blot analysis showed increased expression levels of stem cell factor (SCF), JAK2 and STAT3 in the liver. These results indicated that Shengxuening Tablets promoted the recovery of hematopoietic function in myelosuppressive models by increasing the secretion of hematopoietic factors and activating the JAK2/STAT3 pathway. Therefore, in order to further confirm the preventive effect, effectiveness and safety of Shengxuening Tablets in the treatment of anemia in patients with hematological tumors complicated with anemia, this clinical trial was designed.

Inclusion Criteria:

• Age>18 years old, gender is not limited;
• Patients diagnosed with blood cancer complicated with anemia;
• During the screening period of ≤1 week, hemoglobin (Hb): 60g/L<Hb≤100g/L;
• Willingness to treat

Exclusion Criteria:

• During the screening period of ≤1 week, hemoglobin (Hb)≤60g/L
• History of blood transfusion within 1 month;
• Urgent blood transfusion or EPO infusion is required within the screening period of ≤1 week;
• Folic acid or vitamin B12 deficiency;
• History of iron allergy, history of allergy or intolerance to the study drug;
• Pregnant and lactating women;
• Age <18 years old and body weight ≤35kg;
• Participated in other clinical drug research in the past 3 months;
• Severe cardiac insufficiency (NYHA grade III or above);
• Severe abnormal liver function (ALT, AST and TBIL ≥ 2 times the upper limit of normal value);
• Severe renal insufficiency (creatinine clearance ≤ 15ml/min);
• Severe mental disorder;
• Acute and chronic blood loss;
• Combined with a second tumor;
• Ferritin>500μg/L;
• Combined with active tuberculosis;
• Failure to cooperate with treatment according to doctor's advice.